James E. Krause

Affiliations: 
Washington University School of Medicine, St. Louis, MO, United States 
Google:
"James Krause"
Mean distance: 17.39 (cluster 11)
 
SNBCP
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Hodgetts KJ, Ge P, Yoon T, et al. (2011) Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist. Journal of Medicinal Chemistry. 54: 4187-206
Hodgetts KJ, Blum CA, Caldwell T, et al. (2010) Pyrido[2,3-b]pyrazines, discovery of TRPV1 antagonists with reduced potential for the formation of reactive metabolites. Bioorganic & Medicinal Chemistry Letters. 20: 4359-63
Blum CA, Caldwell T, Zheng X, et al. (2010) Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists. Journal of Medicinal Chemistry. 53: 3330-48
Almarestani L, Waters SM, Krause JE, et al. (2009) De novo expression of the neurokinin 1 receptor in spinal lamina I pyramidal neurons in polyarthritis. The Journal of Comparative Neurology. 514: 284-95
Cortright DN, Meade R, Waters SM, et al. (2009) C5a, but not C3a, increases VEGF secretion in ARPE-19 human retinal pigment epithelial cells. Current Eye Research. 34: 57-61
Krause JE, Chenard BL. (2008) Opportunities and challenges in the discovery of new central nervous system drugs. Annals of the New York Academy of Sciences. 1144: 243-50
Broom DC, Matson DJ, Bradshaw E, et al. (2008) Characterization of N-(adamantan-1-ylmethyl)-5-[(3R-amino-pyrrolidin-1-yl)methyl]-2-chloro-benzamide, a P2X7 antagonist in animal models of pain and inflammation. The Journal of Pharmacology and Experimental Therapeutics. 327: 620-33
Brodbeck RM, Cortright DN, Kieltyka AP, et al. (2008) Identification and characterization of NDT 9513727 [N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a novel, orally bioavailable C5a receptor inverse agonist. The Journal of Pharmacology and Experimental Therapeutics. 327: 898-909
Guo Q, Chandrasekhar J, Ihle D, et al. (2008) 1-Benzylbenzimidazoles: the discovery of a novel series of bradykinin B(1) receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 18: 5027-31
Yoon T, De Lombaert S, Brodbeck R, et al. (2008) 2-Arylpyrimidines: novel CRF-1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 18: 4486-90
See more...